ESMO 2022 | Latest updates in mTNBC

Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, provides an overview of the latest advances in metastatic triple-negative breast cancer (mTNBC), including the emergence of tumor targeting as well as the use of antibody-drug conjugates and immune checkpoint inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.